We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit
EUCRU

Delisted

EUCRU was delisted on the 26th of April, 2023.

Back to rankings

13 hedge funds and large institutions have $11.4M invested in Eucrates Biomedical Acquisition Corp. Unit in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

24% less funds holding

Funds holding: 17 → 13 (-4)

29% less capital invested

Capital invested by funds: $16.1M → $11.4M (-$4.67M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
13
Holders Change
-4
Holders Change %
-23.53%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
4
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
+$27.9K
2
SIA
Schechter Investment Advisors
Michigan
+$24.1K
3
CCM
Condor Capital Management
New Jersey
+$7.97K
4
WC
Wealthspring Capital
New York
+$2.17K

Top Sellers

Rank Fund Capital Flow
1
MF
Magnetar Financial
Illinois
-$3.93M
2
SMA
Sage Mountain Advisors
Georgia
-$860K
3
UBS Group
UBS Group
Switzerland
-$2K
4
TRCT
Tower Research Capital (TRC)
New York
-$1K
5
WAM
Wolverine Asset Management
Illinois
-$897

EUCRU Hedge Fund Activity: Q3 2022 in Review

13 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q3 2022, worth a combined $11.4M — down 29% from $16.1M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of EUCRU and 0 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 4 added.

The largest buyer was Glazer Capital LLC, adding an estimated $27.9K. The largest seller was Magnetar Financial, exiting entirely with an estimated $3.93M sold.

  • 13 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q3 2022, down from 17 in Q2 2022.
  • Funds reported $11.4M of Eucrates Biomedical Acquisition Corp. Unit stock for Q3 2022, down 29% quarter-over-quarter.
  • 0 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q3 2022 and 4 closed out, a net change of -4 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q3 2022 was Glazer Capital LLC, an estimated $27.9K added.
  • The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q3 2022 was Magnetar Financial, an estimated $3.93M sold.

Based on aggregated 13F filings for Q3 2022.